Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer.

Autor: Hanna PE; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Strohbehn IA; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Moreno D; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Harden D; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Seethapathy R; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Sawtell R; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Wang Q; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Ouyang T; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Katz-Agranov N; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Dinulos J; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Wander SA; Massachusetts General Hospital, Department of Medicine, Division of Hematology and Oncology, Boston, MA, USA., Gupta S; Brigham and Women's Hospital Department of Medicine, Division of Renal Medicine, Boston, MA, USA.; Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, MA, USA., Sise ME; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA. msise@mgb.org.
Jazyk: angličtina
Zdroj: NPJ breast cancer [NPJ Breast Cancer] 2023 Aug 19; Vol. 9 (1), pp. 70. Date of Electronic Publication: 2023 Aug 19.
DOI: 10.1038/s41523-023-00576-5
Abstrakt: Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: